Live
- Heavy snow forecast in Japan through Tuesday
- Legendary film-maker Shyam Benegal is no more
- Hackers steal over $12.7 billion in over 1,000 crypto heists to date
- BGT: 'Rohit is short of confidence with self-doubts', opines Manjrekar
- Gold gains 30 pc in 2024, silver 35 pc up on COMEX this year: MOFSL
- Delhi HC dismisses anticipatory bail plea of ex-IAS trainee officer Puja Khedkar
- Untouched Goa Beaches You Must Visit in January
- Muzigal launches its State-of-the-art Music Academy in Nallagandla, Hyderabad
- Thoughtful Christmas Gifts for Every Loved One
- South Korea: Finance minister silent on martial law probe amid speculation on acting president's role
Alembic Pharma gets USFDA nod for insomnia treatment drug
Highlights
Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for Temazepam capsules, used for treatment of insomnia
Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for Temazepam capsules, used for treatment of insomnia.
The company has got approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 7.5mg, 15mg, 22.5mg and 40mg, Alembic Pharmaceuticals said in a BSE filing.
The approved abbreviated new drug application (ANDA) is the therapeutic equivalent to the reference listed drug product (RLD) Restoril Capsules.
Quoting IQVIA sales data, the company said, Temazepam capsules 7.5mg, 15mg, 22.5mg and 40mg had an estimated market size of USD 48 million for 12 months, ending December 2017.
The company's stock was trading at Rs 567 apiece, up 1.33 per cent, on the BSE.
Next Story
ADVERTISEMENT
